Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Revance Therapeutics, Inc.
< Previous
1
2
Next >
Revance to Participate in the Needham 22nd Annual Healthcare Conference
April 05, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Publishes its 2022 Environmental, Social, and Governance (ESG) Report
March 30, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance to Participate in Upcoming Investor Conferences
March 07, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update
February 28, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Adds Experienced Pharmaceutical Executive to Board of Directors with Appointment of Dr. Vlad Coric, M.D., as Independent Director
February 28, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance to Participate in the 43rd Annual Cowen Healthcare Conference
February 27, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance to Present New Data on DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia at the Association of Academic Physiatrists Annual Meeting
February 23, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023
February 21, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results
January 09, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
January 06, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance to Participate in the 34th Annual Piper Sandler Healthcare Conference
November 22, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance to Participate in the Stifel 2022 Healthcare Conference
November 09, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Reports Third Quarter 2022 Financial Results, Provides Corporate Update
November 08, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Announces Two Publications in The Aesthetic Surgery Journal That Advance Glabellar Line Injection Technique and Assessment
November 04, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance to Release Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
November 01, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Submits Supplemental Biologics License Application (sBLA) for DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
October 20, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Appoints David A. Hollander, M.D., M.B.A. as Chief Medical Officer
October 17, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance to Present Clinical Data on the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting
October 10, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance to Participate in the Guggenheim Nantucket Therapeutics Conference
September 21, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) For Injection in the Aesthetic Surgery Journal
September 19, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance to Present Data from Phase 2 JUNIPER Clinical Trial Evaluating DAXXIFY™ (DaxibotulinumtoxinA-lanm) Injection for the Treatment of Upper Limb Spasticity at the International Congress of Parkinson and Movement Disorder Society (MDS)
September 15, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
September 15, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Announces Pricing of $200.0 Million Upsized Public Offering of Common Stock
September 12, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Announces Proposed Public Offering of Common Stock
September 12, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection, the First and Only Peptide-Formulated Neuromodulator With Long-Lasting Results
September 08, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update
August 09, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
August 02, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance To Present Clinical Data on DaxibotulinumtoxinA for Injection at the 2022 TOXINS International Conference
July 27, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance to Participate in the William Blair 42nd Annual Growth Stock Conference
May 23, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
Revance Reports First Quarter 2022 Financial Results, Provides Corporate Update
May 10, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Tickers
RVNC
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.